← Back to Search

GLP-1 Receptor Agonist

LY3502970 for Type 2 Diabetes

Phase 2
Waitlist Available
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up pre-dose (week (wk) 0, wk 8, wk 12, and wk 26); post-dose (wk 4, wk 8, wk 16, wk 20, and end of treatment).
Awards & highlights

Study Summary

This study is evaluating whether a drug can help people with diabetes.

Eligible Conditions
  • Type 2 Diabetes

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~pre-dose (week (wk) 0, wk 8, wk 12, and wk 26); post-dose (wk 4, wk 8, wk 16, wk 20, and end of treatment).
This trial's timeline: 3 weeks for screening, Varies for treatment, and pre-dose (week (wk) 0, wk 8, wk 12, and wk 26); post-dose (wk 4, wk 8, wk 16, wk 20, and end of treatment). for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change From Baseline in HbA1c in LY3502970 as Compared to Placebo
Secondary outcome measures
Change From Baseline in Body Weight
Change From Baseline in Fasting Serum Glucose
Change From Baseline in HbA1c in LY3502970 as Compared to Dulaglutide
+3 more

Side effects data

From 2022 Phase 2 trial • 383 Patients • NCT05048719
37%
Nausea
33%
Vomiting
26%
Diarrhoea
22%
Constipation
19%
Eructation
11%
Weight decreased
11%
Flatulence
11%
Dyspepsia
7%
Abdominal distension
7%
Haemoglobin decreased
7%
Decreased appetite
7%
Abdominal pain upper
7%
Retching
7%
Asthenia
7%
Urticaria
4%
Hypertension
4%
Arthralgia
4%
Fatigue
4%
Ischaemic stroke
4%
Lipase increased
4%
Palpitations
100%
80%
60%
40%
20%
0%
Study treatment Arm
36 mg LY3502970 - 1
12 mg LY3502970
24 mg LY3502970
36 mg LY3502970 - 2
45 mg LY3502970 - 1
Placebo
3 mg LY3502970
45 mg LY3502970 - 2
1.5 mg Dulaglutide

Trial Design

9Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: 45 mg LY3502970 - 2Experimental Treatment1 Intervention
Participants received maintenance dose 45 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally QD.
Group II: 45 mg LY3502970 - 1Experimental Treatment1 Intervention
Participants received maintenance dose 45 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally QD.
Group III: 36 mg LY3502970 - 2Experimental Treatment1 Intervention
Participants received maintenance dose 36 mg with dose escalation starting from 3 mg, 6 mg,12 mg, 24 mg and then 36 mg LY3502970 administered orally QD.
Group IV: 36 mg LY3502970 - 1Experimental Treatment1 Intervention
Participants received maintenance dose 36 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 8 mg, 12 mg, 24 mg and then 36 mg LY3502970 administered orally QD.
Group V: 3 milligrams (mg) LY3502970Experimental Treatment1 Intervention
Participants received maintenance dose of 3 mg with dose escalation starting from 2 mg LY3502970 administered orally once daily (QD).
Group VI: 24 mg LY3502970Experimental Treatment1 Intervention
Participants received maintenance dose 24 mg with dose escalation starting from 3 mg, 6 mg, 8 mg,12 mg and then 24 mg LY3502970 administered orally QD.
Group VII: 12 mg LY3502970Experimental Treatment1 Intervention
Participants received maintenance dose 12 mg with dose escalation starting from 2 mg, 6 mg and then 12 mg LY3502970 administered orally QD.
Group VIII: 1.5 mg DulaglutideActive Control1 Intervention
Participants received 1.5 mg Dulaglutide administered subcutaneously (SC) once weekly (QW).
Group IX: PlaceboPlacebo Group1 Intervention
Participants received matching placebo.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
LY3502970
2021
Completed Phase 2
~1220

Find a Location

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,615 Previous Clinical Trials
3,200,675 Total Patients Enrolled
Study DirectorEli Lilly and Company
1,344 Previous Clinical Trials
404,869 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What state do they live in?
Texas
How old are they?
18 - 65
What site did they apply to?
Biopharma Informatic, LLC
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
A Study of LY3502970 in Participants With Type 2 Diabetes Mellitus
2021. "A Study of LY3502970 in Participants With Type 2 Diabetes Mellitus". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05048719.
~107 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top